Conference Coverage

VIDEO: Assessment tool rapidly screens lupus cognition


 

AT THE EULAR 2015 CONGRESS

References

ROME – The Montreal Cognitive Assessment provides a quick and easy-to-use screening tool to identify patients with systemic lupus erythematosus with cognitive impairment, Dr. Zahi Touma reported in a poster at the European Congress of Rheumatology.

In a consecutive series of 78 patients screened with the Montreal Cognitive Assessment (MoCA), the free, single-page test, which can be administered in about 10 minutes, showed a sensitivity of 69% and specificity of 68%, compared with the current standard, the Hopkins Verbal Learning Test-Revised, said Dr. Touma, a rheumatologist at the University of Toronto.

Other easy-to-use and quick screening tools, such as the Mini-Mental State Examination, had substantially worse performance in the study. He and his associates found a sensitivity of 21% and specificity of 91% using the Mini-Mental State exam. For screening, higher sensitivity is desirable so that fewer patients with potential cognitive impairment are missed, he noted.

“Ease of use and time needed for assessment as well as appropriate psychometric properties make the MoCA the preferential screening test for cognitive impairment in patients with SLE,” Dr. Touma said in his poster.

Cognitive impairment is very common among patients with systemic lupus erythematosus (SLE). In this study, Dr Touma found a 47% prevalence using MoCA. Cognitive impairment, however, often goes unidentified in SLE patients, likely because of lack of awareness among rheumatologists as well as the absence of a quick and easily administered screening tool, he said in a video interview.

Dr. Touma said he hopes that the apparent efficacy of an easy-to-use screening tool like MoCA will help boost appreciation for the high prevalence of cognitive impairment in SLE patients. He suggested that clinicians screen for cognitive impairment as soon as SLE is diagnosed and that they perform follow-up screening during subsequent patient encounters with SLE patients who initially present without cognitive impairment.

Dr. Touma had no disclosures.

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

mzoler@frontlinemedcom.com

On Twitter @mitchelzoler

Recommended Reading

ATS: Nintedanib found effective for IPF up to 76 weeks
MDedge Rheumatology
BSR: Flagging early symptoms could diagnose lupus sooner
MDedge Rheumatology
Rate ratio of comorbidity high in SLE patients under 40
MDedge Rheumatology
Nonprofits launch web campaign to raise awareness about scleroderma
MDedge Rheumatology
Rontalizumab effective in interferon signature matrix–low SLE patients
MDedge Rheumatology
Chronic anemia associated with high PAP in SLE patients
MDedge Rheumatology
Mycophenolate mofetil bests azathioprine for maintenance in lupus nephritis
MDedge Rheumatology
VIDEO: Do pathogenic intestinal bacteria drive scleroderma GI symptoms?
MDedge Rheumatology
First gut microbiota alterations described in systemic sclerosis patients
MDedge Rheumatology
Uncomplicated pregnancies in women with lupus may not boost risk for CV events
MDedge Rheumatology